Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12613000289718
Ethics application status
Approved
Date submitted
8/03/2013
Date registered
14/03/2013
Date last updated
19/05/2014
Type of registration
Prospectively registered

Titles & IDs
Public title
Treatment of Patent Ductus Arteriosus with Paracetamol
Scientific title
Paracetamol for patent ductus arteriosus treatment: comparison between oral and intravenous administration
Secondary ID [1] 281991 0
Nil
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Patent ductus arteriosus in very low birth weight neonates 288426 0
Condition category
Condition code
Reproductive Health and Childbirth 288774 288774 0 0
Complications of newborn
Cardiovascular 288939 288939 0 0
Other cardiovascular diseases

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Intravenous paracetamol at a loading dose of 20 mg/kg, followed by 7.5 mg/kg every 6 hours for 7 days. Paracetamol formulation that will be used is a commercially available product intended for parenteral administration (Perfalgan; Bristol- Myers Squibb, Munich, Germany), delivered in vials containing 50 ml of solution corresponding to 500 mg of paracetamol (10 mg of paracetamol in 1 ml of solution). If ductal closure evaluated by color-doppler ultrasound occurs before the seventh day of treatment, therapy will be discontinued.
Intervention code [1] 286560 0
Treatment: Drugs
Comparator / control treatment
Paracetamol at 15 mg/kg by oral route, every 6 hours for 7 days. Paracetamol formulation that will be used is a commercially available product intended for enteral administration (Tachipirina 100 mg/ml; Angelini, Rome, Italy), delivered in drops (3 mg of paracetamol in 1 drops), diluted in 2 ml of sterile water, administered via an orogastric tube, which will be flushed with further 1-2 mL of sterile water to ensure delivery of the drug into the stomach. If ductal closure evaluated by color-doppler ultrasound occurs before the seventh day of treatment, therapy will be discontinued.
Control group
Active

Outcomes
Primary outcome [1] 288910 0
Ductal closure, assessed by color-doppler ultrasound
Timepoint [1] 288910 0
At 7 days after allocation to the intervention
Secondary outcome [1] 301310 0
Mortality
Timepoint [1] 301310 0
42 weeks of postconception age

Eligibility
Key inclusion criteria
Neonates with gestational age < 32 weeks and birth weight < 1500 g and with echocardiographic evidence of patent ductus arteriosus and contraindication to or failure of conventional medical therapy with COX inhibitors (ibuprofen or indomethacin) consecutively observed in Neonatal Intensive Care Unit are eligible for the trial. In all infants, color-doppler ultrasound will be performed at 24-48 hrs after birth to evaluate patency of ductus arteriosus and shunting. Elegibility of a neonate is defined by the presence at color-doppler ultrasound of at last one of the following criteria: 1. transductal diameter =/>1.5 mm, 2. reverse diastolic flow or absent diastolic flow in the descending aorta or in the superior mesenteric artery, anterior or middle cerebral arteries or renal artery, 3. unrestrictive pulsatile transductal flow (DA V max <2 m/s), 4. left-atrium-to-aortic-root ratio =/>1.5. Controindications to NSAIDs therapy are: reduced urine output (< 1 ml/kg/h) during the preceding 8 hours or other signs of renal failure, liver failure, intraventricular hemorrhage, a platelet count < 60,000/mm3, hyperbilirubinemia (defined as total bilirubin > 15 mg/dl), gastrointestinal bleeding and signs of feeding intolerance. Failure of NSAIDs treatment is defined by the presence of a patent ductus at the end of a single course of treatment with ibuprofen (loading dose at 10 mg/kg, followed by 5 mg/kg at 24 and 48 hours) or indomethacin (three doses at 0,2 mg/kg every 12 hours).
Minimum age
1 Days
Maximum age
5 Days
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Liver disease, hemolytic anemia, family history of G6PD deficiency

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Enrolled neonates will be assigned to Group 1 (intravenous paracetamol) or to Group 2 (enteral paracetamol) according to a computerized and centralized randomization list. Each patient will be coded with a number reported in the randomization list. Researchers assessing ductal closure by echocardiographic examination will be unaware for study aims and group assignment. The data for the evaluation of treatment efficacy and safety will be recorded on data sheets especially designed for this study and labeled with the name of the enrolled neonate and with the randomization list code. Group assignment will be concealed until statistical analysis will be completed.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Computer generated randomization list
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s

The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis
The Kolmogorov-Smirnov test will be used to determine if variables are normally distributed. For continuous variables, groups will be compared using the test of equality of means, the Mann-Whitney test and Kruskal-Wallis test. The chi-square test and Fisher’s exact test will be used for categorical variables. For two related dichotomous variables, the McNemar test will be used to detect differences between study groups. We will perform a multivariate analysis (binary logistic regression) to evaluate whether PDA closure would be influenced by GA, modality of delivery, multiple birth, BW, sex, Apgar score at 5 minutes, or by study group assignment. The level of significance for all statistical tests is 2-sided, p<0.05. Statistical analysis will be performed, per intention-to-treat, by a statistician blinded to patient group assignment with SPSS Version 16.0 for Windows (SPSS Inc., Chicago, IL).

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
1/04/2013
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
90
Accrual to date
Final
Recruitment outside Australia
Country [1] 4877 0
Italy
State/province [1] 4877 0

Funding & Sponsors
Funding source category [1] 286769 0
University
Name [1] 286769 0
Sapienza, University of Rome
Country [1] 286769 0
Italy
Primary sponsor type
University
Name
Sapienza University of Rome
Address
Piazzale Aldo Moro, 5 00161 Rome
Country
Italy
Secondary sponsor category [1] 285549 0
Hospital
Name [1] 285549 0
Department of Gynecology-Obstetrics and Perinatal Medicine - Policlinico Umberto I
Address [1] 285549 0
Viale del Policlinico, 155, 00161 Rome
Country [1] 285549 0
Italy

Ethics approval
Ethics application status
Approved

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 38002 0
Prof Gianluca Terrin
Address 38002 0
Department of Gynecology-Obstetrics and Perinatal Medicine, Sapienza University of Rome, Italy
Viale del Policlinico, 155 00161 Rome
Country 38002 0
Italy
Phone 38002 0
+39 06 499 72521
Fax 38002 0
+39 06 3377 6660
Email 38002 0
[email protected]
Contact person for public queries
Name 38003 0
Gianluca Terrin
Address 38003 0
Department of Gynecology-Obstetrics and Perinatal Medicine, La Sapienza University of Rome, Italy
Viale del Policlinico, 155 00161 Rome
Country 38003 0
Italy
Phone 38003 0
+39 06 499 72521
Fax 38003 0
+39 06 3377 6660
Email 38003 0
[email protected]
Contact person for scientific queries
Name 38004 0
Gianluca Terrin
Address 38004 0
Department of Gynecology-Obstetrics and Perinatal Medicine, La Sapienza University of Rome, Italy
Viale del Policlinico, 155 00161 Rome
Country 38004 0
Italy
Phone 38004 0
+39 06 499 72521
Fax 38004 0
+39 06 3377 6660
Email 38004 0
[email protected]

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
SourceTitleYear of PublicationDOI
EmbaseParacetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants.2022https://dx.doi.org/10.1002/14651858.CD010061.pub5
N.B. These documents automatically identified may not have been verified by the study sponsor.